Biosimilars LatAm – Brazil 2025

As a platform for advancing access to biosimilars in Brazil, this forum convenes senior executives and key stakeholders from the pharmaceutical and regulatory sectors to examine strategies for consolidating Brazil’s leadership in the global biosimilars market. Through engaging panels, expert presentations, and networking sessions, the event explores the role of international alliances, the contributions of ANVISA and academic institutions, and solutions for overcoming regulatory and market challenges to ensure global distribution.

Key Objectives:

– Analyze how alliances with international entities facilitate entry into new markets.

– Discuss the role of ANVISA and universities in fostering research and developing bioprocess talent.

– Address strategies for navigating regulatory and market challenges to enable global distribution of biosimilars.

Who will
you meet?

More than:

Participants

Companies

HCPs

Patients

Academy

Investors

Institutions

Associations

Service Providers

Government Agencies

Industry Executives from Latam

From these areas:

Biosimilars
Biobetters
Biotechnology
Biotherapeutics
Analytical science
Regulatory compliance
Quality Control
Clinical immunology
Scientific Affairs
Pharmacovigilance
Research
Regulatory
Business Development
Marketing

Plan Your 1-to-1 Meetings with JackLeckerman App

Speaker Board 2024

Program at a Glance

Data Box: Understanding INN Suffixes for New Antibodies

Data box : Market Penetration of Biosimilars in Latin America

Aligning Brazilian Compliance with EMA Standards for European Market Access

Explore strategies for aligning Brazilian biosimilars with EMA regulatory standards.

Strategic Alliances for Brazilian Biosimilars’ Global Expansio

Analyze how alliances with foreign entities facilitate entry into new markets.

Strengthening Talent through ANVISA and Academia

Discuss how ANVISA and universities support research and bioprocess talent development.

Regulatory Synergy in Brazil’s Biosimilars Landscape

Highlighting how innovation in R&D, combined with streamlined regulatory pathways, can accelerate biosimilar development and market entry within Brazil.

Full Programme in the PDF Agenda

Download Agenda

Download Agenda

Sartorius

Based in Goettingen | Germany, Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With its two divisions Lab Products & Services and Bioprocess Solutions, Sartorius helps customers to manufacture biotech medicines, vaccines, and cell and gene therapies safely, rapidly, and economically.

Visit Website

Sponsor the Forum in 2025

Photo Gallery from Previous Events

Open Gallery

104PHBIBR19-photo-gallery-2018-desktop-01

Testimonials

”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”

Alison Bascou, Sr. Regulatory Director at BD, France
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."

Jaime Uribe, CEO At PROBIOMED
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”

Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”

Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”

Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico